Website Logo

Press

Keep up-to-date with relevant news, important announcements and key market insights.

READ MORE
FEATURED

The Guardian – Partnering with patients on their rare disease journey

Download here

About Bionical Emas

Bionical Emas is the only Contract Research Organization that combines Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) to deliver a unique, seamless approach to bring life-changing medicines to patients around the world.

READ MORE

The Guardian - Partnering with patients on their rare disease journey

READ MORE

Women in Healthcare - PharmaTimes May 2023

READ MORE

The Guardian - Inviting patients as equal partners in the drug development process

READ MORE

Tom Watson appointed Chief Executive Officer

READ MORE

Carl Hvass appointed Chief Financial Officer

READ MORE

Women in Healthcare - PharmaTimes May 2022

READ MORE

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

READ MORE

Bionical Emas to establish European storage, distribution and labelling facility in Co. Westmeath

READ MORE

Women in Healthcare - PharmaTimes May 2021

READ MORE

Bionical Emas launches Expanded Access Program for JZP458 – a recombinant Erwinia Asparaginase

READ MORE

Bionical Emas introduces Veeva Vault Safety

READ MORE

Bionical Emas launches Managed Access Program for JZP 458 – a recombinant Crisantaspase produced in Pseudomonas fluorescens